Bayer's Kerendia Hopes Rest on Translating Trial Subgroups Into Prescriptions
Published on 09/02/2026 at 12:11 | Editorial boerse-global.de
The German healthcare group's shares are hovering barely above their 50-day moving average, a muted response that captures the market's ambivalence toward what could be either a transformative growth asset or a promising but ultimately niche therapy.
Bayer presented fresh subgroup analyses from the Phase III FIND-CKD study at the European Society of Cardiology congress in Munich, where the company fielded eleven presentations including several late-breaking analyses on chronic kidney disease. The data showed that finerenone, marketed as Kerendia, slowed the decline in kidney function among patients with hypertensive nephropathy compared with placebo.
That patient population — individuals whose kidneys have been damaged by chronic high blood pressure rather than diabetes — represents a meaningful expansion of the drug's potential addressable market. The commercial stakes are considerable: Kerendia generated €603 million in first-half 2026 revenue, up 75 percent year on year.
A Growth Engine Built on a Modest Base
The drug's momentum matters because the rest of the pharma division is treading water. Second-quarter group sales rose a modest 2.2 percent on a currency- and portfolio-adjusted basis to €10.9 billion, while core earnings per share fell 16.7 percent to €0.95, dragged down by a higher tax rate and weaker segment results. Bayer reaffirmed its full-year guidance of €44.7 billion to €47.0 billion in revenue and core EPS between €4.10 and €4.80, with the pharma unit expected to grow no more than 3 percent on a currency-adjusted basis.
Should investors sell immediately? Or is it worth buying Bayer?
The 75 percent growth rate, impressive as it is, comes off a relatively small base within a group of Bayer's scale. Whether that trajectory holds as the label potentially expands to additional kidney indications will determine whether Kerendia becomes the structural replacement for revenues lost to patent expiries elsewhere in the portfolio — or remains a bright spot that cannot fully offset weaknesses in other divisions.
Balance Sheet Relief Creates Running Room
The bull case rests on two reinforcing developments. First, the ESC data provide scientific substance that could translate into regulatory label expansions, widening the market for a drug already growing rapidly. Second, the €3.0 billion capital injection from Apollo Global Management agreed in July has eased balance sheet pressure, with Bayer trimming its year-end net debt guidance from €32–33 billion to €29–30 billion.
That deleveraging creates financial flexibility to fund growth areas such as Kerendia and Perfuse Therapeutics, the acquisition announced in May for up to $2.45 billion. A combination of shrinking debt and a growing pharma contribution could narrow the gap to the stock's 52-week high of €53.86, from which the shares currently sit roughly 10 percent lower.
The Legal Overhang Refuses to Clear
The bear case is equally clear-eyed about the fragility of the narrative. Subgroup analyses are scientific presentations, not regulatory decisions — positive signals from one data cut do not guarantee approval expansions. And the glyphosate litigation remains unresolved: the fairness hearing for final approval of the $7.25 billion class settlement has been pushed to September 14 after Bayer and plaintiffs' attorneys jointly requested more time to process opt-out revocation requests following the Supreme Court's June ruling.
That procedural step underscores that even after the preemption decision favored Bayer, open questions remain. The settlement is not yet final and binding — it depends on judicial review. Should the hearing slip again or go against the company, investors who had priced in a cleanup of this risk factor would face renewed uncertainty.
Two Test Dates, One Verdict
The immediate catalysts are now clear. The September 14 court hearing will determine whether the glyphosate overhang finally lifts, while the coming quarters will show whether Kerendia can sustain its growth pace beyond the diabetes indication that has driven sales to date. The share price, trading at €48.72 against a 50-day average of €48.57, suggests investors are withholding judgment until both questions resolve. If either falters — weaker Kerendia momentum or fresh legal delays — the market will likely reassess the valuation. If both hold, the current level near the moving average could prove a platform for further stabilization.
Ad
Bayer Stock: New Analysis - 2 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
